Nurix Therapeutics’ BTK degrader has elicited responses in a small group of patients with certain cancers, supporting the biotech’s claim that the drug could potentially …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As I reported on Friday evening, Lykos looks set to appeal the FDA’s decision. The company said it will request a meeting with the agency to ask
A study presented at the recent American Society of Clinical Oncology (ASCO) annual meeting found that mirvetuximab soravtansine (Elahere), an antibody and microtubule inhibitor conjugate,
Geopolitical tensions and threats of decoupling have led to a steep decline in American companies’ confidence in working with Chinese partners, although few have taken